Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Aug 26, 2026
•
4 min read
Plus: Zymeworks banks $250M and falls 7%. Bristol Myers walks.
Aug 25, 2026
5 min read
Alzheimer's gets a blood test, Regenxbio gets five bad MRIs, Munich opens Friday.
Aug 24, 2026
Non-incretin obesity, a GOP letter aimed at China trial data, and Capricor’s PDUFA comes and goes.
Aug 21, 2026
Roche commits $750M to a plant that won't fill a syringe until 2031.
Aug 20, 2026
Moderna adds $44B of market cap in a session, and the FDA hands out two firsts.
Aug 19, 2026
Overton heads for a Senate fight, and a third China trial death surfaces.
Aug 18, 2026
Duravyu's primary miss, a PD-1/VEGF curve that shrank, and AstraZeneca finally printing a win.
Aug 17, 2026
Capricor doubles on an FDA reprieve, and Redx backs into Nasdaq with $125M.
Aug 14, 2026
Zipalertinib clears Phase 3, and the FDA puts a price on where you run Phase 1.
